The aim of this study was to generate maraviroc (MVC)-resistant viruses in vitro using a human immunodeficiency virus type 1 subtype B clinical isolate (HIV-1 ) to understand the mechanism(s) of resistance to MVC. To select HIV-1 variants resistant to MVC in vitro, we exposed high-chemokine (C-C motif) receptor 5 (CCR5)-expressing PM1/CCR5 cells to HIV-1 KP-5 followed by serial passage in the presence of MVC. We also passaged HIV-1 KP-5 in PM1 cells, which were low CCR5 expressing to determine low-CCR5-adapted substitutions and compared the Env sequences of the MVC-selected variants. Following 48 passages with MVC (10 mM), HIV-1 KP-5 acquired a resistant phenotype [maximal per cent inhibition (MPI) 24 %], whilst the low-CCR5-adapted variant had low sensitivity to MVC (IC 50~2 00 nM), but not reduction of the MPI. The common substitutions observed in both the MVC-selected and low-CCR5-adapted variants were selected from the quasi-species, in V1, V3 and V5. After 14 passages, the MVCselected variants harboured substitutions around the CCR5 N-terminal-binding site and V3 (V200I, T297I, K305R and M434I). The low-CCR5-adapted infectious clone became sensitive to anti-CD4bs and CD4i mAbs, but not to anti-V3 mAb and autologous plasma IgGs. Conversely, the MVC-selected clone became highly sensitive to the anti-envelope (Env) mAbs tested and the autologous plasma IgGs. These findings suggest that the four MVC-resistant mutations required for entry using MVC-bound CCR5 result in a conformational change of Env that is associated with a phenotype sensitive to anti-Env neutralizing antibodies.
INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) entry into target cells is triggered by the interaction of the viral envelope glycoproteins (Env) with its receptor CD4 and one or two major coreceptors, chemokine (C-C motif) receptor 5 (CCR5) or chemokine (C-X-C motif) receptor 4 (CXCR4), and culminates in fusion of the viral and cell membranes. Env is organized into trimers on virions, and consists of the gp120 surface and gp41 transmembrane subunits (Wyatt & Sodroski, 1998) . The small-molecule CCR5 antagonist maraviroc (MVC) was the first CCR5 inhibitor licensed for clinical use . CCR5 inhibitors work by allosterically altering the conformation of CCR5 at the cell surface, thereby disrupting its interaction with HIV gp120 (Berger et al., 1999; Dorr et al., 2005) . Although MVC and another CCR5 inhibitor, vicriviroc (VCV), can efficiently suppress HIV-1 replication, resistant variants can arise both in vitro and in vivo, and these resistant viruses are adapted to use drug-bound CCR5 for entry (Berro et al., 2009; Kuhmann et al., 2004; Marozsan et al., 2005; Ogert et al., 2009 Ogert et al., , 2010 Ratcliff et al., 2013; Roche et al., 2011b; Tilton et al., 2010; Tsibris et al., 2008; Westby et al., 2007; Yuan et al., 2011; Yusa et al., 2005) . Current models of gp120 binding to a coreceptor suggest that the crown of the gp120 V3 loop interacts principally with the second extracellular loop region of the coreceptor, whilst the gp120 bridging sheet, which is formed after CD4 binding, and the stem of the V3 loop interact with the N terminus of the coreceptor (Brelot et al., 1999; Cormier & Dragic, 2002; Farzan et al., 1999; Huang et al., 2005) . The development of resistance is an important issue for HIV treatment regimens incorporating MVC, as is the case for any antimicrobial agent.
HIV-1 can develop clinical resistance to CCR5 antagonists by two routes. The first pathway is through emergence of pre-existing CXCR4-using viruses (Fätkenheuer et al., 2008; Landovitz et al., 2008; Westby et al., 2006) . CCR5 inhibitor evasion can also occur by the accumulation of multiple mutations in gp120 and/or gp41 without a switch in coreceptor usage (Dragic et al., 2000; Maeda et al., 2006 Maeda et al., , 2008a Roche et al., 2011b; Tsamis et al., 2003) . The resistant pathway is characterized not by shifts in IC 50 (a competitive inhibitor), but rather by reductions in the maximal per cent inhibition (MPI). Reductions in MPI are due to the resistant virus developing the ability to bind to the antagonistmodified form of CCR5 (Westby et al., 2007) . However, one study reported that chimeric clones bearing the N425K mutation in C4 replicated at high MVC concentrations and displayed significant shifts in IC 50 s, characteristic of resistance to all other antiretroviral drugs, but not MVC (Ratcliff et al., 2013) .
Escape mutants to the CCR5 inhibitor, AD101 (SCH-350581), have been found to be more sensitive than the parental isolate to a subset of neutralizing mAbs against V3 and a CD4-induced (CD4i) epitope (Pugach et al., 2007; Berro et al., 2009) . To date, however, it is not clear which mutation(s) induced by MVC affect the accessibility of neutralizing mAbs to the epitopes in Env.
Therefore, to determine the resistance mechanisms to MVC, we passaged a primary CCR5-tropic (R5) subtype B isolate in the high-CCR5-expressing T-cell line PM1/CCR5 in the presence of MVC (Fig. S1 , available in the online Supplementary Material) and compared the Env sequences of variants with those cultured in the low-CCR5-expressing parental PM1 cell line (Fig. S1 ). We also investigated the phenotypic change in the MVC-resistant clone against antiEnv antibodies, especially for anti-V3 neutralizing mAbs and autologous plasma IgGs, and compared the results with the low-CCR5-adapted clone to determine the key mutations for accessibility of neutralizing mAbs to the epitopes in Env.
RESULTS
Anti-HIV-1 activities of MVC toward laboratory strains and primary HIV-1 isolates Initially, we determined the MPI and the IC 50 values of MVC against different laboratory-adapted and primary HIV-1 isolates, including both CXCR4-tropic (X4) and R5 viruses. MVC inhibited the laboratory-adapted HIV-1 R5 strains HIV-1 BaL and HIV-1 JR-FL with MPIs of 98 and 97 %, respectively, but did not inhibit the X4 virus HIV-1 IIIB or dual-tropic virus HIV-1 89.6 (MPI ,20 %, Table 1 ). We also tested MVC against 14 R5 primary isolates, including subtypes B, C and G, and the circulating recombinant form CRF08_BC. MVC effectively inhibited all of these primary isolates at concentrations of 1.2-26 nM (MPI 92-100 %), but did not inhibit three primary X4 isolates (two CRF01_AE and one subtype B) with MPI ,20 % (Table 1) .
Selection of MVC-resistant variants
To select MVC-resistant HIV-1 variants in vitro, we exposed PM1/CCR5 cells to HIV-1 , which had the highest IC 50 value (26 nM) and lowest MPI (92 %) among the primary isolates tested, and serially passaged the viruses in the presence of increasing concentrations of MVC. As a control, HIV-1 was passaged under the same conditions without MVC in PM1/CCR5 cells (designated the passage control). Moreover, to compare the differences between the MVC-resistant variant and low-CCR5-expressing-cell-adapted variant, we passaged HIV-1 KP-5 in low-CCR5-expressing parental PM1 cells (designated low-CCR5-adapted). The selected virus was initially propagated in the presence of 1 nM MVC and during the course of the selection procedure the concentration of MVC was increased to 10 mM over 48 passages (Fig. 1a) .
Resistance to small-molecule CCR5 inhibitors is known to vary according to the cell type used (Anastassopoulou We also determined the sequential MPIs and IC 50 values of each passaged variant to MVC (Fig. 2) . From passages ) were exposed to 100 TCID 50 of each variant and cultured in the presence or absence of various concentrations of the drug in 96-well microculture plates. The amounts of p24 antigen produced by the cells were determined on day 7. All assays were performed in triplicate.
1 to 14, the MVC-selected and low-CCR5-adapted variants had almost equal IC 50 values and the MPIs were high. After 16 passages, the IC 50 values of the MVCselected variants continued to increase to .10 mM, whilst the MPIs decreased to 24 % at 48 passages, especially after 27 passages. The low-CCR5-adapted variants maintained an IC 50 value of~200 nM and high MPIs (90-100 %) until the end of the experiment (passage 48). Conversely, the passage control variants did not show remarkable changes in their IC 50 values and MPIs throughout the passages (IC 50 values of~20 nM, MPI 95-100 %). The low-CCR5-adapted variant was also resistant to two other CCR5 inhibitors, APL and TAK-779 (data not shown).
These findings suggested that the phenotype of the MVCselected variants under low concentrations of the drug corresponded with that of the low-CCR5-adapted variants until 14 passages; then, under high concentrations, the MVC-selected variants acquired additional mutations for high resistance to the CCR5 inhibitor.
Comparison of the Env region sequences of the MVC-selected and low-CCR5-adapted mutants
To determine the genetic basis of the resistance in the HIV-1 KP-5 variants and compare the substitutions between the MVC-selected and low-CCR5-adapted variants, the Env genes were sequenced (Figs 3, 4 and S2). At 17 passages, all substitutions in both the MVC-selected and low-CCR5-adapted variants were selected from the baseline viruses. Five of these substitutions in gp120, i.e. K8R, C11W (signal peptide), D141N (V1), E321D (V3) and I463T (V5), were observed in both passaged variants. Conversely, at positions 137 (K or E), 148 (Q or K) and 187 (G or D), the amino acids differed between the MVC-selected and low-CCR5-adapted variants. After 16 passages, the MVCselected variants acquired four additional mutations, i.e. T297I (V3), M434I (C4), V200I (C2) and K305R (V3), at passages 17, 21, 34 and 41, respectively, which were not observed in the low-CCR5-adapted variants (Figs 2-4 and S2). After acquisition of M434I in C4 (21 passages), the MPI of the MVC-selected variants decreased gradually (from 74 to 24 %) (Fig. 2) . The most important amino acid substitution for the reduction in the MPI might be K305R, because the MPI of the variant cultured without MVC after 48 passages increased by reverting from R to K at position 305 (data not shown). Three additional mutations, i.e. F317W (V3), V84I (C1) and A436T (C4), were observed in the low-CCR5-adapted variants at 17, 21 and 48 passages, respectively. These mutations might be compensatory for viral fitness following culture in the low-CCR5-expressing cells, because the MPIs of the variants with these three mutations did not differ from those of the variants prior to the acquisition of these mutations (.90 %).
These findings suggest that under low concentrations of MVC, the variants were selected from the baseline viruses similarly to the low-CCR5-adapted variants (IC 50 shift and high MPI), whilst under high concentrations of the drug, the selected variants required additional mutations to use drug-bound coreceptors for entry into the target cells.
To compare the two mutation profiles obtained from the MVC-selected and low-CCR5-adapted variants at 48 passages, the crystal structure of gp120 was used (Figs 3 and 4). Comparison of the sequences of the two passaged variants based on the Protein Data Bank (PDB ID: 2B4C) crystal structure of gp120 showed that the MVC-selected variant harboured many substitutions within and around the V3 region, i.e. the CCR5 N-terminal-binding site, compared with the low-CCR5-adapted variant in the threedimensional (3D) position. In a magnification of the CCR5 N-terminal-binding site (Fig. 4) , three of four mutations, i.e. T297I, M434I and V200I, were concentrated around the V3 base and finally K305R appeared in the V3 stem region after 41 passages.
To determine the positions of MVC-selected mutations in the gp120 trimer form, we illustrated the sites of mutations on the structure of the BG505 SOSIP trimer obtained from the PDB (ID: 3J5M) ( Fig. S3 ) (Lyumkis et al., 2013) . Almost all of the MVC-selected mutations occurred at the upper and outer side of the trimer. Several MVC-selected mutations, i.e. V65K, V200I, K305R, M309I, F317L and M434I, lay relatively close to the neighbouring gp120. These findings demonstrated that these mutations may affect trimer formation and expose neutralizing antibody epitopes.
Susceptibilities of the infectious clones with mutant Env to anti-Env mAbs
In a previous study, a CCR5 inhibitor (AD101)-resistant infectious clone was sensitive to neutralization via V3 and 
: Substitutions observed in the MVC-selected variant. : Substitutions observed in both the MVC-selected and low-CCR5-adapted variants. : Substitutions observed in the low-CCR5-adapted variant. Fig. 3 . Comparison of the locations of the mutations in the MVC-selected and low-CCR5-adapted gp120. The side chains of the mutated residues that appeared during the MVC selection (left) and low CCR5 adaptation (right) are shown in yellow (only MVC selection), pink (only low CCR5 adaptation) and green (both). A summary schema is also provided.
CD4i epitopes (Berro et al., 2009) . To examine whether our three passaged variants became sensitive to anti-Env mAbs, we constructed three infectious clones with each 48-passaged Env (Fig. 5) . The clone with the Env of the MVCselected variant showed a low MPI (56 %) under a high concentration of MVC, which was also seen with the passage control and low-CCR5-adapted clones (Fig. 5a ). Using these infectious clones, we tested the susceptibilities to the anti-Env mAbs b12 [anti-CD4 binding site (antiCD4bs)], 4E9C (anti-CD4i) and KD-247 (anti-V3). As shown in Fig. 5(b) , the MVC-selected and low-CCR5-adapted clones showed higher sensitivity to b12 than the passage control clone, with IC 50 values of 0.22, 0.31 and 0.86 mg ml
21
, respectively. The MVC-selected and low-CCR5-adapted clones became highly sensitive to 4E9C compared with the passage control clone (IC 50 values of 0.08, 0.41 and .5 mg ml 21 , respectively) (Fig. 5c) . Moreover, the clone with the MVC-selected Env was highly sensitive to anti-V3 mAb KD-247, while the low-CCR5-adapted and passage control clones were not (IC 50 values of 0.04, .100 and .100 mg ml 21 , respectively) (Fig. 5d ).
These findings indicated that the MVC-selected clone with its greater number of mutations might contribute to exposure of neutralizing epitopes for these three mAbs, whilst the low-CCR5-adapted mutations could change the conformation of Env to become sensitive to anti-CD4i and CD4bs mAbs, but not anti-V3 mAb.
Susceptibilities of the infectious clones with mutant Env to autologous plasma IgGs
We also examined whether the infectious clones with the passaged Env mutations were neutralized by autologous plasma IgGs. As shown in Fig. 6(a) , none of the autologous plasma IgGs could neutralize the passage control clone at concentrations up to 100 mg ml
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. In the low-CCR5-adapted clone, some of the plasma IgGs slightly inhibited the replication of the virus under high concentrations, but did not reach the 50 % inhibition level (Fig. 6b) . Conversely, all seven plasma IgGs were able to completely neutralize the clone with the MVC-selected Env (IC 50 2.6-37 mg ml
, MPI 79-97 %) (Fig. 6c) .
These findings show that the MVC-selected clone with the greater number of mutations also might contribute to exposure of neutralizing epitopes for autologous plasma IgGs. 
DISCUSSION
The CCR5 inhibitors, MCV and VCV, are allosteric inhibitors of virus entry, hence resistance to these drugs is evidenced by a reduction in the plateau of virus inhibition curves rather than by increases in IC 50 (Dragic et al., 2000; Maeda et al., 2006 Maeda et al., , 2008a Roche et al., 2011b; Tsamis et al., 2003) . One study reported that resistant mechanisms contribute to the altered recognition of drug-bound CCR5 by an MVC-resistant HIV-1 strain. This study demonstrated very efficient usage of drug-bound CCR5, characterized by increased dependence on the CCR5 N terminus (Tilton et al., 2010) . Another report demonstrated a similar yet distinct mechanism of escape from MVC by MVCresistant Env, with comparatively less efficient usage of drug-bound CCR5 (Roche et al., 2011b) . In the absence of the drug, MVC-resistant Env maintains a highly efficient interaction with CCR5, similar to that of MVC-sensitive Env, and displays a relatively modest increase in dependence on the CCR5 N terminus (Roche et al., 2011b) . However, in the presence of the drug, MVC-resistant Env interacts much less efficiently with CCR5 and becomes critically dependent on the CCR5 N terminus. In the current study, we induced MVC-resistant HIV-1, which harboured many substitutions within and around the V3 region, i.e. the CCR5 N-terminalbinding site in vitro. In order to determine whether the resistant variant displayed an increased CCR5 N-terminal dependence, we determined the sensitivity of each variant to anti-CCR5 N-terminal mAb, CTC-5. All passaged variants were completely resistant to CTC-5; however, the MVCselected variant became sensitive to CTC-5 when MVC (1 mM) was added in the assay, as reported previously (Berro et al., 2009) . These results suggest that the four mutations associated with the CCR5-binding site in the MVC-selected variant might create an increased dependency on interaction with the CCR5 N terminus.
In this study, we attempted to determine the difference between the MVC-selected and low-CCR5-adapted variants in parallel using an in vitro passage system. Under low concentrations of MVC, the MPI reduction was not observed in either the MVC-selected variant or the low-CCR5-adapted variant, although both passaged variants had common substitutions in the V1, V3 and V5 regions from quasi-species. Compared with the baseline viruses, under high concentrations of MVC, the resistant variants acquired mutations within the area of the CCR5-binding site in gp120 by evolution and/or selection from minor subsets. Following acquisition of the latter mutations, the variants with mutant Env showed a considerably reduced MPI (24 %). These results indicate that mutants arising from passage in low-CCR5-expressing cells can influence the IC 50 shift, but not a reduction in the MPI.
One previous study showed that although numerous changes were observed in V3 and other regions of gp160, genotypic analysis of the cloned env sequences revealed no specific mutational pattern associated with reduced susceptibility to VCV in a phase 2 clinical trial (Pantophlet & Burton, 2006) . Using the Los Alamos Database, we found that the frequencies of the four mutations occurred in ,10 % of 1501 subtype B viruses (V200I, 5.1 %; T297I, 5.9 %; K305R, 9.5 %; M434I, 2.5 %). Assays for these mutations might provide useful clinical markers for determining the sensitivity of HIV-1 to MVC. One limitation of the present study was that only one primary isolate was used and a single in vitro passage series was used for variant selection. Further studies using multiple isolates and multiple passage cultures are required to determine if this MVC-susceptibility model applies to other HIV subtypes and cell systems. Ogert et al. (2009) and Anastassopoulou et al. (2009) reported that multistep resistance mutations during in vitro selection that reduced the MPI values to VCV were driven by the K305R substitution and the H308P substitution was related to a reduction in the MPI plateau level to VCV resistance. Henrich et al. (2010) also reported such mutations in vivo, as S306P was not detected in the baseline virus population, but was necessary for maximal resistance when incorporated into V3 backbones that included pre-existing VCV resistance mutations. Our in vitro study also showed that the K305R mutation contributed to maximal resistance to MVC when incorporated into V3 and CCR5 N-terminal-binding site backbones that included pre-existing MVC resistance mutations. Moreover, our MVC-selected variant with MVC (1 mM) became sensitive to the CCR5 N-terminal mAb (data not shown). Conversely, Roche et al. (2011a) reported that the MVC-resistant variants increased reliance on sulfated tyrosine residues in the CCR5 N terminus without common gp120 resistance mutations. One resistant clone (17-Res) harboured I317F, A322D and I323V substitutions in the V3 loop, whilst the other resistant clone (24-Res) had P308S and Ala inserted at the 313 position in the V3. In our MVCresistant variant, we found some mutations at the same positions (305, 309, 317 and 321) in the V3 region as those of 17-Res and 24-Res clones (Roche et al., 2011a) . It is still not clear whether such mutations around the V3 loop stem region contribute to increased reliance on the CCR5 N terminus, and further studies are needed to determine the relationship between each mutation and CCR5 N terminus dependency.
HIV Env evades antibody recognition of conserved epitopes by several means, including decoration with a dense glycan shield, hypervariable loops that mask conserved features and high intrinsic conformational dynamics that render it a poorly defined antigen (Pantophlet & Burton, 2006) . In the present study, the infectious clone with the Env of the low-CCR5-adapted virus became sensitive to anti-CD4i mAb, but not anti-V3 mAb and autologous plasma IgGs. Conversely, the clone with the highly MVC-resistant Env was neutralized by the anti-V3 mAb at low concentrations (,0.1 mg ml
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) and also by the autologous plasma IgGs. These findings suggest that the low-CCR5-adapted mutations are related to accessibility of the anti-CD4i mAb to its epitopes, whilst the greater number of mutations in the MVC-selected virus may provide access to the epitopes of not only anti-CD4bs and anti-CD4i mAbs, but also the anti-V3 mAb and autologous plasma IgGs. In preliminary data, we have confirmed the presence of such anti-CD4i and anti-V3 antibodies in plasma samples from the subject from whom HIV-1 KP-5 was isolated (unpublished data). In vivo, where potent levels of Env neutralizing antibodies may be present, the MVC-selected variants may become neutralization-sensitive and not survive. For this reason, it is possible that CCR5 inhibitors, such as MVC, suppress HIV replication for long periods, especially in patients with high levels of circulating anti-Env neutralizing antibodies prior to treatment with MVC.
As some of the mutations in the MVC-selected variant are close to the epitope for KD-247, those mutations might influence the sensitivity and/or binding affinity to KD-247. Moreover, the mutations around and within the V3 loop may also affect the association with the V2 loop by opening of the trimer. Our study did not allow us to distinguish this possibility. Thus, further studies with single and combinations of mutations in Env to determine the binding affinity to the neutralizing antibodies by FACS and/or ELISA are ongoing.
Following CD4 binding, the CD4-binding site on gp120 becomes ordered and the bridging sheet subdomain forms, drawing the V1/V2 loops into a 'down' orientation and positioning them alongside CD4 (Guttman et al., 2012) . The MVC-selected variant in our study became highly sensitive to anti-CD4i and V3 neutralizing mAbs compared with the passage control virus. Further analysis of the effect of the CCR5 inhibitor-resistant Env to neutralizing antibodies would be of interest because, as reported in our previous work (Yoshimura et al., 2006) , the anti-V3 mAb KD-247-resistant variant became highly sensitive to CCR5 inhibitors.
METHODS
Viruses. Primary HIV-1 viruses were isolated from patients and passaged in PHA-activated PBMCs. Infected PBMCs were co-cultured for 5 days with PM1/CCR5 cells and the culture supernatants were stored at -150 uC until use . HIV-1 KP-5 was isolated from a subject prior to MVC therapy but who has subsequently been taking combination antiretroviral therapy containing MVC since September 2009. The HIV-1 KP-5 was isolated before starting the combination antiretroviral therapy.
Cells, culture conditions and reagents. The CD4 + T-cell line PM1 (Lusso et al., 1995) was obtained through the AIDS Research and Reference Reagent Program (ARRRP). The PM1/CCR5 cell line was a kind gift from Dr Yosuke Maeda (Kumamoto University, Kumamoto, Japan) (Maeda et al., 2008b) . The CCR5 inhibitor MVC was kindly provided by Pfizer (Groton, CT, USA).
Flow cytometric analysis. PM1 and PM1/CCR5 cells were analysed for surface expression of CCR5 and CXCR4. The cells (5610 5 ) were incubated with phycoerythrin-labelled anti-CCR5 mAb 2D7, phycoerythrin-labelled anti-CXCR4 mAb 12G5 or isotype-matched control mAbs (BD Biosciences) and analysed using a FACSCalibur (Becton Dickinson).
In vitro selection of HIV-1 variants using anti-HIV drugs. HIV-1 KP-5 was infected into PM1/CCR5 cells and treated with various concentrations of MVC to induce the production of MVC-resistant variants as described previously (Harada et al., 2013; Hatada et al., 2010; Yoshimura et al., 2006 Yoshimura et al., , 2010 , with minor modifications. Briefly, PM1/CCR5 cells (4610 4 ) were exposed to 500 TCID 50 HIV-1 and cultured in the presence of MVC. The culture supernatant was harvested on day 7 and used to infect fresh PM1/CCR5 cells for the next round of culture in the presence of increasing concentrations of MVC. We also passaged the virus in the absence of MVC in PM1/ CCR5 cells and the parental cell line PM1. Proviral DNA was extracted from lysates of infected cells at different passages and subjected to nucleotide sequencing.
Amplification of proviral DNA and nucleotide sequencing.
Proviral DNA was subjected to PCR amplification using PrimeSTAR GXL DNA polymerase and Ex-Taq polymerase (Takara) as described previously (Harada et al., 2013; Hatada et al., 2010; Yoshimura et al., 2006 Yoshimura et al., , 2010 . Primers 1B and H were used for the gp120 region (Harada et al., 2013; Hatada et al., 2010) . The first-round PCR products were used directly in a second round of PCR using primers 2B and F for gp120 (Harada et al., 2013; Hatada et al., 2010) . The second-round PCR products were purified and cloned into the pGEM-T Easy Vector (Promega), and the env region in each passaged virus was sequenced using a 3500xL Genetic Analyzer (Applied Biosystems).
Susceptibility assay. The sensitivities of the passaged viruses to various drugs were determined as described previously (Harada et al., 2013; Hatada et al., 2010; Yoshimura et al., 2006 Yoshimura et al., , 2010 , with minor modifications. Briefly, PM1/CCR5 cells were plated in 96-well roundbottom plates (2610 3 cells per well), exposed to 100 TCID 50 of the viruses in the presence of various concentrations of drugs and incubated at 37 uC for 7 days. The IC 50 values were then determined using a Cell Counting kit-8 (WST-8 assay; Dojindo Laboratories). All assays were performed in duplicate or triplicate.
PHA-activated PBMCs (1610 6 cells ml 21 ) were exposed to 100 TCID 50 of each HIV-1 strain and cultured in the presence or absence of various concentrations of drugs in 96-well microculture plates. The concentration of p24 antigen produced by the cells was determined on day 7 using a Lumipulse F system (Fujirebio) (Maeda et al., 2001) . IC 50 values were determined by comparison with the p24 production level in drug-free control cell cultures (Shirasaka et al., 1995) . All assays were performed in triplicate.
Construction of chimeric NL4-3/KP-5 env proviruses. Chimeric proviruses were constructed from the pNL4-3 proviral plasmid (ARRRP) by overlapping PCR as described previously (Shibata et al., 2007) , with minor modifications. Briefly, the gp160 coding sequences were amplified from the cloning vectors using the primers EnvFv (59-AGCAGAAGACAGTGGCAATGAGAGCGAAG-39) and EnvR (59-TTTTGACCACTTGCCACCCATCTTATAGC-39). A portion of the NL4-3 provirus spanning nt 5284-6232 was amplified with primers NL(5284)F (59-GGTCAGGGAGTCTCCATAGAATGGAGG-39) and NL(6232)Rv (59-CTTCGCTCTCATTGCCACTGTCTTCTGCT-39). This fragment encompasses the unique EcoRI restriction site in pNL4-3. Another fragment from the NL4-3 provirus spanning nt 8779-9045 was amplified using the primers NL(8779)F (5-GCTATAAGATGGGTGGCAAGTGGTCAAAA-3) and NL(9045)R (5-GATCTACAGCTGCCTTGTAAGTCATTGGTC-3). This fragment includes the unique XhoI restriction site in pNL4-3. Overlapping PCR was used to join the gp160 coding sequence from the desired clone to the fragment encompassing nt 8779-9045 that had been amplified from pNL4-3. The resulting fragment was then similarly joined to the amplified fragment encompassing nt 5284-6232 from pNL4-3.
The sensitivities of the three infectious clones to KD-247 (anti-V3 mAb) (Eda et al., 2006) , b12 (anti-CD4bs mAb; kindly provided by
